Shares in Acorda Therapeutics (NSDQ:ACOR) fell today after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results.
The Ardsley, N.Y.-based company posted a net loss of -$18.9 million, or -41¢ per share, on sales of $119.4 million for the 3 months ended March 31. In the same quarter last year, Acorda reported a net loss of -$0.5 million on sales of $115.9 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda misses on Q1 earnings, slashes expense guidance after restructuring appeared first on MassDevice.